FluorouracilDocetaxelTrastuzumabEllenceCarboplatinRegimensTaxanesRegimenDaunorubicinDoxorubicin or epirubicinCytoxanCisplatinNeoadjuvantHydrochloride InjectionTaxane-basedNonanthracycline-basedBreast cancerPatientsToxicityDosesTreatmentMedicationsCancerAlkylating agentsSevereAntibioticsTherapySupervision of a doctor
Fluorouracil14
- 85% for historical regimens (ie, cyclophosphamide/methotrexate/fluorouracil) are known to affect breast cancer survival. (jnccn.org)
- In patients with breast cancer receiving adjuvant 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel (FEC-D), we evaluated the impact of chemotherapy total cumulative dose (TCD), and early (FEC) versus late (D only) dose reductions, on survival outcomes. (jnccn.org)
- Landmark meta-analyses by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) initially showed a 20% to 25% relative risk reduction in breast cancer mortality for first-generation regimens (ie, cyclophosphamide/methotrexate/fluorouracil [CMF]) and increased benefit with the addition of anthracyclines and taxanes. (jnccn.org)
- This study sought to retrospectively characterize outcomes for patients with node-negative and node-positive breast cancer receiving adjuvant trastuzumab in combination with docetaxel/cyclophosphamide (DCH), docetaxel/carboplatin/trastuzumab (TCH), or fluorouracil/epirubicin/cyclophosphamide followed by docetaxel/trastuzumab (FEC-DH) chemotherapy in Alberta, Canada, from 2007 through 2014. (jnccn.org)
- Many studies have reported anthracycline-based regimens increase the benefits compared to cyclophosphamide, methotrexate, and fluorouracil combinations. (kjco.org)
- 10 ] compared the oncologic outcome of the various regimens in adjuvant CTx (cyclophosphamide, methotrexate, and fluorouracil combination, anthracycline-based regimens, taxane-anthracycline-based regimens, dose-dense taxane-anthracycline-based regimens). (kjco.org)
- In the use of chemotherapy drugs, anthracyclines, such as doxorubicin and epirubicin, are generally used in combination with drugs such as cyclophosphamide, epirubicin, and fluorouracil. (encyclopedia.pub)
- Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. (hemonc.org)
- All patients postoperatively received four cycles of the four weekly i.v. CMF regimen (cyclophosphamide, methotrexate, and 5-fluorouracil). (ox.ac.uk)
- As with other cytotoxic agents, Epirubicin Hydrochloride Injection at the recommended dose in combination with cyclophosphamide and fluorouracil can produce severe leukopenia and neutropenia. (recallguide.org)
- A total of 102 patients with resectable early-stage breast cancer was treated with NAC consisting of FEC (5-fluorouracil, epirubicin, and cyclophosphamide) followed by weekly paclitaxel before surgery. (biomedcentral.com)
- The following combinations of chemotherapy drugs may be used for advanced breast cancer: CAF (or FAC) - cyclophosphamide, doxorubicin and 5-fluorouracil CEF (or FEC) - cyclophosphamide, epirubicin and 5-fluorouracil AC - doxorubicin and cyclophosphamide EC - … 2014-04-16 Hospice care workers provide palliative care, but palliative care can be given at any time during an illness, not just at the end of life. (web.app)
- It's most often given with both cyclophosphamide and fluorouracil. (aultcare.com)
- Adjuvant polychemotherapy (e.g. with 58% to 68%) for patients under the age of 50.1 Besides an cyclophosphamide, methotrexate and 5-fluorouracil (CMF)) or improvement in clinical outcome, these figures indicate that anthracycline-containing regimes, produce substantial reduc- a large proportion of the patients will never recur after the tion in recurrence and mortality. (lu.se)
Docetaxel5
- 101 patients received neoadjuvant chemotherapy with docetaxel and doxorubicin, 46 patients received with epirubicin and paclitaxel. (kjco.org)
- following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
- Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. (revistarevisionesencancer.com)
- Its being used (& FDA approved) in the treatment of adjuvant in colorectal cancer , metastatic colorectal cancer and Metastatic breast cancer - used in combination with docetaxel, after failure of anthracycline-based treatment. (med-chemist.com)
- The pre-planned three-year interim analysis of a randomised, prospective trial compared adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for the treatment of early breast cancer with the standard, non-capecitabine regimen (docetaxel, epirubicin, cyclophosphamide and fluorouracil). (med-chemist.com)
Trastuzumab7
- The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens. (rxlist.com)
- We also review the data the efficacy and safety of anthracycline-based and nonanthracycline-based adjuvant chemotherapy regimens combined with trastuzumab, and optimum chemotherapy regimens in small HER2-positive tumors. (carcinogenesis.com)
- Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. (hemonc.org)
- Tell your doctor and pharmacist if you are taking or have ever received certain cancer chemotherapy medications such as daunorubicin (Cerubidine), doxorubicin (Doxil), idarubicin (Idamycin), mitoxantrone (Novantrone), cyclophosphamide (Cytoxan), or trastuzumab (Herceptin). (medlineplus.gov)
- The patients' malignancies, mostly breast cancer but one case of leukemia, had been successfully treated with cyclophosphamide or trastuzumab (Herceptin, Genentech) or the anthracyclines doxorubicin or epirubicin (Ellence, Pfizer). (medscape.com)
- Following surgery and anthracycline-based chemotherapy, participants will receive either trastuzumab emtansine at a dose of 3.6 milligrams per kilogram (mg/kg) and pertuzumab at a dose of 420 milligrams (mg) intravenously (IV) every 3 weeks (q3w) or trastuzumab at a dose of 6 mg/kg and pertuzumab at a dose of 420 mg IV q3w in combination with a taxane. (roche.com)
- Cardiotoxicity can be classified as non-reversible that leads to progressive systolic heart failure and is most typically caused by anthracyclines and reversible cardiac dysfunction hpv mouth symptoms pictures resolves for most patients over time by interrupting anticancer therapy and administering specific cardiac treatment the best known anticancer agent that causes reversible cardiotoxicity is trastuzumab. (leacurinaturiste.ro)
Ellence4
- Another form of treatment - anthracycline chemotherapy - uses doxorubicin , daunorubicin (Cerubidine), epirubicin (Ellence), and idarubicin (Idamycin). (dreamsfertility.com)
- Ellence (epirubicin) is an anthracycline, which intercalates into DNA and inhibits topoisomerase II ( PMID: 24367159 ). (jax.org)
- Ellence (epirubicin) is FDA approved as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement for primary breast cancer (FDA.gov). (jax.org)
- Epirubicin [Ellence] has a unique AE. (freezingblue.com)
Carboplatin2
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per- Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). (revistarevisionesencancer.com)
- Pathologic complete response rates were significantly increased in the pembrolizumab group in the intention-to-treat population, with the addition of pembrolizumab being associated with an increase to 64.8%, compared with 51.2% in the control arm (placebo plus paclitaxel and once weekly or every-3-week carboplatin, followed by doxorubicin or epirubicin plus cyclophosphamide). (ascopost.com)
Regimens5
- With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. (carcinogenesis.com)
- In the group with 4-10 positive lymph nodes, the results showed improvement in the oncologic outcomes with taxane-anthracycline-based regimens. (kjco.org)
- In the group of more than 11 lymph nodes, the results showed improvements in the oncologic outcomes with dose-dense taxane-anthracycline based regimens. (kjco.org)
- Systemic adjuvant chemotherapy with anthracycline- and taxane-containing regimens has become the standard first line treatment for early and metastatic breast cancer [ 5 ], with large phase III randomized trials showing extremely high long-term disease-free survival and overall survival rates (resp. (hindawi.com)
- Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens inWomen With ERBB2/HER2-Negative Breast Cancer- The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial. (revistarevisionesencancer.com)
Taxanes1
- The taxanes have been used to improve treatment outcomes alone or with anthracycline [ 7 - 9 ]. (kjco.org)
Regimen6
- Additionally, National Comprehensive Cancer Network (NCCN) Guidelines currently recommend cisplatin/doxorubicin/cyclophosphamide as the primary treatment regimen. (medscape.com)
- The aim of this study is to evaluate the prognostic factors of the group who received neoadjuvant chemotherapy with a taxane-anthracycline combination regimen. (kjco.org)
- We retrospectively analyzed for locally advanced breast cancer patients who received neoadjuvant chemotherapy with adjuvant extension with taxane-anthracycline combination regimen. (kjco.org)
- In order to predict an oncologic outcome from locally advanced breast cancer patients who are treated with neoadjuvant chemotherapy with taxane-anthracycline based regimen, we can use pathologic complete response, an early response to neoadjuvant chemotherapy. (kjco.org)
- These results overall suggest that the use of scalp cooling is effective in preventing alopecia in the majority of early breast cancer patients receiving neoadjuvant or adjuvant CT, especially for patients undergoing a taxane-based non-anthracycline regimen. (plkinhibitors.com)
- A previous retrospective study reported a 12.4% rate of pCR among 139 triple-negative IBC patients specifically, though this study used an anthracycline-containing regimen. (medpagetoday.com)
Daunorubicin1
- tell your doctor and pharmacist if you are allergic to epirubicin, daunorubicin (Cerubidine, DaunoXome), doxorubicin (Doxil), idarubicin (Idamycin), any other medications, or any of the ingredients in epirubicin injection. (medlineplus.gov)
Doxorubicin or epirubicin1
- And other studies have shown how certain chemotherapy drugs, for example anthracyclines, such as doxorubicin or epirubicin, or drugs such as cyclophosphamide, can damage the left ventricle of the heart, causing lowered levels of blood to be pumped. (canceractive.com)
Cytoxan2
- Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). (jax.org)
- Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). (jax.org)
Cisplatin1
- [ 40 ] The patients were treated with adjuvant or neoadjuvant chemotherapy with cisplatin, epirubicin hydrochloride, and etoposide. (medscape.com)
Neoadjuvant1
- 6 Anthracycline is one of the most widely used drugs for chemotherapy, often in combination with cyclophosphamide and taxane as adjuvant or neoadjuvant therapy. (omjournal.org)
Hydrochloride Injection5
- Epirubicin Hydrochloride Injection should be administered only under the supervision of qualified physicians experienced in the use of cytotoxic therapy. (recallguide.org)
- Total and differential WBC, red blood cell (RBC), and platelet counts should be assessed before and during each cycle of therapy with Epirubicin Hydrochloride Injection. (recallguide.org)
- This toxicity appears to be dependent on the cumulative dose of Epirubicin Hydrochloride Injection and represents the cumulative dose-limiting toxicity of the drug. (recallguide.org)
- If it occurs, delayed cardiotoxicity usually develops late in the course of therapy with Epirubicin Hydrochloride Injection or within 2 to 3 months after completion of treatment, but later events (several months to years after treatment termination) have been reported. (recallguide.org)
- In a retrospective survey, including 9144 patients, mostly with solid tumors in advanced stages, the probability of developing CHF increased with increasing cumulative doses of Epirubicin Hydrochloride Injection (Figure 5). (recallguide.org)
Taxane-based1
- This threshold, in addition to early versus late dose reductions, are poorly defined for third-generation anthracycline/taxane-based chemotherapy. (jnccn.org)
Nonanthracycline-based1
- So, the question [is:] do you want to give anthracycline-based therapy versus nonanthracycline-based treatment? (targetedonc.com)
Breast cancer9
- Some examples of oral chemo drugs for breast cancer include: cyclophosphamide. (knowbreastcancer.org)
- PURPOSE: To investigate the relationship of hypoxia-inducible factor-1alpha (HIF-1alpha) tumor expression in predicting the response to epirubicin and disease-free survival (DFS) in patients with breast cancer enrolled in a single institution trial of primary anthracycline and tamoxifen therapy. (ox.ac.uk)
- EXPERIMENTAL DESIGN: The expression of HIF-1alpha was assessed by immunohistochemistry in 187 patients with T(2-4) N(0-1) breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin + tamoxifen as primary systemic treatment. (ox.ac.uk)
- Epirubicin is used in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. (medlineplus.gov)
- We investigate the incidence of hematological toxicities and their relation to the haplotype ATP-binding cassette B1 (ABCB1) which were polymorphisms of C1236T , C3435T , G2677T, and glutathione S-transferase P1 ( GSTP1 ) A313G genes in Indonesian breast cancer patients who received anthracycline during chemotherapy. (omjournal.org)
- Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/ USOR 07132, and NSABP B-49 (NRG Oncology). (revistarevisionesencancer.com)
- As conventional formulation: As a component of adjuvant therapy (multi-agent) in women with axillary lymph node involvement following resection of primary breast cancer: In combination with cyclophosphamide: 60 mg/m 2 on day 1 of each 21-day treatment cycle, for a total of 4 cycles. (azurewebsites.net)
- Progressive symptomatic breast cancer after adjuvant anthracycline-based chemotherapy. (web.app)
- Second or third line treatment of metastatic breast cancer after previous combination chemotherapy with an anthracycline in patient who has an ECOG status of less than or equal to 2 and a life expectancy greater than three months. (web.app)
Patients2
- Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. (who.int)
- Before beginning treatment with epirubicin, patients should recover from acute toxicities (such as stomatitis, neutropenia, thrombocytopenia, and generalized infections) of prior cytotoxic treatment. (recallguide.org)
Toxicity4
- A dose-dependent, reversible leukopenia and/or neutropenia is the predominant manifestation of hematologic toxicity associated with epirubicin and represents the most common acute dose-limiting toxicity of this drug. (recallguide.org)
- Anthracycline-induced cardiac toxicity may be manifested by early (or acute) or late (delayed) events. (recallguide.org)
- Early cardiac toxicity of epirubicin consists mainly of sinus tachycardia and/or ECG abnormalities such as non-specific ST-T wave changes, but tachyarrhythmias, including premature ventricular contractions and ventricular tachycardia, bradycardia, as well as atrioventricular and bundle-branch block have also been reported. (recallguide.org)
- palifermin increases toxicity of epirubicin by Other (see comment). (medscape.com)
Doses1
- Epirubicin may increase your risk for developing leukemia (cancer of the white blood cells), especially when it is given in high doses or together with certain other chemotherapy medications. (medlineplus.gov)
Treatment7
- doxorubicin , cyclophosphamide , and paclitaxel) led to higher rates of recovery from treatment-induced amenorrhea. (dreamsfertility.com)
- Epirubicin may cause serious or life-threatening heart problems at any time during your treatment or months to years after your treatment has ended. (medlineplus.gov)
- Your doctor will order tests before and during your treatment to see if your heart is working well enough for you to safely receive epirubicin. (medlineplus.gov)
- Cardiotoxicity is a known risk of anthracycline treatment. (recallguide.org)
- These effects do not usually predict subsequent development of delayed cardiotoxicity, are rarely of clinical importance, and are generally not considered an indication for the suspension of epirubicin treatment. (recallguide.org)
- Also as monotherapy, if the patient has failed paclitaxel-based treatment, and if anthracycline-based treatment has either failed or cannot be continued for other reasons. (med-chemist.com)
- The recommended dose of epirubicin varies widely according to the specific condition being treated, the response to therapy, the other medications being used, and the body size of the recipient person receiving treatment. (medbroadcast.com)
Medications3
- Epirubicin should be given only under the supervision of a doctor with experience in the use of chemotherapy medications. (medlineplus.gov)
- Epirubicin is in a class of medications called anthracyclines. (medlineplus.gov)
- Epirubicin comes as a solution (liquid) to be injected intravenously (into a vein) by a doctor or nurse in a medical facility along with other chemotherapy medications. (medlineplus.gov)
Cancer2
- Epirubicin prevents the growth of cancer cells by interfering with the genetic material DNA, which is necessary for reproduction of cells. (medbroadcast.com)
- As well as interfering with the genetic material DNA of cancer cells, epirubicin can interfere with some of your normal cells. (medbroadcast.com)
Alkylating agents1
- A representative of the alkylating agents is cyclophosphamide . (drsymptoms.com)
Severe2
- Epirubicin can cause a severe decrease in the number of blood cells in your bone marrow. (medlineplus.gov)
- Life-threatening CHF is the most severe form of anthracycline-induced cardiomyopathy. (recallguide.org)
Antibiotics2
- Special considerations with anthracycline antitumor antibiotics? (freezingblue.com)
- Anthracycline antitumor antibiotics have a unique AE. (freezingblue.com)
Therapy1
- Anthracycline chemotherapy may occasionally be used with radiation therapy to the chest or upper abdomen. (dreamsfertility.com)
Supervision of a doctor1
- Epirubicin is always given under the supervision of a doctor in a hospital or similar setting with access to sterile equipment for preparation. (medbroadcast.com)